20/20 OptimEyes
20/20 OptimEyes Technologies is a pre-clinical biotechnology spin-out company from McMaster University located in Hamilton, Ontario, Canada. We developed a transformative drug delivery platform for ocular diseases typically controlled by eye drops. Using a patented micelle formulation, we can change the dosing paradigm for eye drops from twice daily to once or twice weekly. Proceeds from this Summit will be used for a small batch manufacturing run to complete CMC and IND-enabling validation of the technology in our lead indication, dry eye disease. This technology will revolutionize treatment for patients, improving their comfort, compliance and clinical outcomes.
Hear more from this company during the Early Technology Showcase.
Presenter: Frances Lasowski, Founder & CEO
Read More
Mediphage Bioceuticals
Mediphage Bioceuticals, a preclinical-stage biotechnology company, is developing the next-generation non-viral gene delivery platform based on its ministring DNA (msDNA) technology. Mediphage’s proprietary msDNA is a versatile gene delivery platform that has the potential for applications in various therapeutic areas including retina, liver, oncology, and CNS disorders among others. msDNA can be used in applications beyond gene therapy, including DNA vaccines to address infectious diseases, improved rAAV platform production, and gene editing. Mediphage is currently raising $32M CAD in Series A which will support executive and technical team growth, process development and proof of concept studies.
Presenter: Alvaro Amorrortu, CEO & President
Read More
Ripple Therapeutics
Ripple Therapeutics is a clinical stage company focused on improving ophthalmic therapeutics with controllable, sustained drug delivery. Ripple’s Epidel® platform is based on a discovery that drugs can be engineered into controlled release pharmaceuticals without polymers or excipients. These proprietary prodrugs undergo surface erosion to give zero order release kinetics and are highly engineerable to tailor drug dose and duration to the specific indication. Ripple’s lead program – IBE-814 IVT – is an intravitreal implant targeting diabetic macular edema (DME) and retinal vein occlusion (RVO). A Phase II trial has been initiated in Australia with the first patient treatment expected early 2021.
Presenter: Wendy Naimark, VP, Research & Development
Read More
